Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 49 of the 53 references it cites were found in a registry or an index.

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML

Open access

Abstract

Myelodysplastic syndromes (MDSs) are clonal hematologic disorders that frequently represent an intermediate disease stage before progression to acute myeloid leukemia (AML). As such, study of MDS/AML can provide insight into the mechanisms of neoplastic evolution. In 184 patients with MDS and AML, DNA methylation microarray and high-density single nucleotide polymorphism array (SNP-A) karyotyping were used to assess the relative contributions of aberrant DNA methylation and chromosomal deletions to tumor-suppressor gene (TSG) silencing during disease progression. Aberrant methylation was seen in every sample, on average affecting 91 of 1505 CpG loci in early MDS and 179 of 1505 loci after blast transformation (refractory anemia with excess blasts [RAEB]/AML). In contrast, chromosome aberrations were seen in 79% of early MDS samples and 90% of RAEB/AML samples, and were not as widely distributed over the genome. Analysis of the most frequently aberrantly methylated genes identified FZD9 as a candidate TSG on chromosome 7. In patients with chromosome deletion at the FZD9 locus, aberrant methylation of the remaining allele was associated with the poorest clinical outcome. These results indicate that aberrant methylation can cooperate with chromosome deletions to silence TSG. However, the ubiquity, extent, and correlation with disease progression suggest that aberrant DNA methylation is the dominant mechanism for TSG silencing and clonal variation in MDS evolution to AML.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2008-06-163246

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

See all 426

Metadata

Authors
Jiang, Y., Dunbar, A., Gondek, L. P., Mohan, S., Rataul, M., O'Keefe, C., Sekeres, M., Saunthararajah, Y., & Maciejewski, J. P.
Affiliations
  • Experimental Hematology and Hematopoiesis Section and
  • Cleveland Clinic (US)
Corresponding author
  • Saunthararajah, Yogen
  • Maciejewski, Jaroslaw P.
Venue
Blood
Published
2009-02-05
Volume
113
Issue
6
Pages
1315-1325
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W1974079495
Cited by
384
References
53
Citations by year
2026: 3 · 2025: 4 · 2024: 3 · 2023: 12 · 2022: 12 · 2021: 19 · 2020: 17 · 2019: 12 · 2018: 20 · 2017: 22 · 2016: 21 · 2015: 24 · 2014: 31 · 2013: 36 · 2012: 43
FWCI
22.72
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (and K24, 1s10rr019391-01, 5r01hl082983-04)
  • National Heart, Lung, and Blood Institute (R01-HL082983, K24HL077522)
  • National Center for Research Resources (U54 RR 019391, S10-RR-019391)
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Keywords
myelodysplastic syndrome, acute myeloid leukemia, aberrant DNA methylation, tumor suppressor gene silencing, chromosomal deletion, FZD9, chromosome 7, clonal evolution, disease progression, refractory anemia with excess blasts, CpG sites, clinical outcomes
MeSH terms
Adolescent, Adult, Aged, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Bone Marrow, Chromosome Aberrations, Female, Humans, Karyotyping, Male, Middle Aged, Myelodysplastic Syndromes, Prognosis, Promoter Regions, Genetic, RNA, Messenger, Tumor Cells, Cultured, Leukemia, Myeloid, Acute, Case-Control Studies, Disease Progression, CpG Islands, DNA Methylation, Reverse Transcriptase Polymerase Chain Reaction, Polymorphism, Single Nucleotide, Tumor Suppressor Proteins, Receptors, G-Protein-Coupled, Microarray Analysis, Frizzled Receptors, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. https://app.cochat.ai/papers/10.1182/blood-2008-06-163246
The paper
Jiang, Y., Dunbar, A., Gondek, L. P., Mohan, S., Rataul, M., O'Keefe, C., Sekeres, M., Saunthararajah, Y., & Maciejewski, J. P. (2009). Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. https://doi.org/10.1182/blood-2008-06-163246

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.